Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | TACR2 | P21452 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9214094 | 1.00 | ACHE (0.40) | ACHEBACE1MGLLFAAHPTGS2 | |
| SCHEMBL9214278 | 1.00 | ACHE (0.40) | ACHEBACE1MGLLFAAHPTGS2 | |
| SCHEMBL9214003 | 1.00 | ACHE (0.40) | ACHEBACE1MGLLFAAHPTGS2 | |
| SCHEMBL9213345 | 1.00 | ACHE (0.40) | ACHEBACE1MGLLFAAHPTGS2 | |
| SCHEMBL9211600 | 1.00 | ACHE (0.40) | ACHEBACE1MGLLFAAHPTGS2 | |
| SCHEMBL9207365 | 1.00 | ACHE (0.40) | ACHEBACE1MGLLFAAHPTGS2 | |
| SCHEMBL5408962 | 0.98 | ACHE (0.37) | ACHEBACE1MGLLFAAHPTGS2 | |
| SCHEMBL5403812 | 0.91 | — | — | |
| SCHEMBL9215037 | 0.89 | MGLL (0.45) | MGLLFAAHALDH1A1 | |
| SCHEMBL9215043 | 0.89 | MGLL (0.45) | MGLLFAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | disclosed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | disclosed |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2020-07-09 | — | — | US | disclosed |
| US-10610533-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3527079-A1 | METHODS OF TREATING ORAL MUCOSITIS | Galera Labs, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2056675-B1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2018-11-22 | — | — | US | disclosed |
| EP-3287464-A1 | ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS | Abbott Laboratories (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9855279-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| EP-2859916-B1 | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy | GALERA LABS LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-1996039396-A1 | MANGANESE OR IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1995028968-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0679155-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE. | MONSANTO CO (US) | 1995-11-02 | — | — | EP | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994015925-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ACHE 797/4885BACE1 4680/4885MGLL 1180/4885 |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ACHE 797/4885BACE1 4680/4885MGLL 1180/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ACHE 797/4885BACE1 4680/4885MGLL 1180/4885 |
| US-10610533-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | ACHE 797/4885BACE1 4680/4885MGLL 1180/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | ACHE 797/4885BACE1 4680/4885MGLL 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.